Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

By John B. Buse, R. Henry, Jenny Han, Dennis D. Kim, M. Fineman, A. Baron. Diabetes Care, 2004

1,402 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/3a70f7249259b667a9794e5fb966a653abbdc8f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Endocrinology, Diabetes and Metabolism

Citations in the corpus

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). (2009, result): “Similar patterns are apparent in other studies.[13-15,18,19] Only two major hypoglycaemic episodes occurred (both in the exenatide group).”
Gut hormones and the regulation of energy homeostasis (2006, background): “Interestingly, in phase III 30-week clinical trials, exenatide significantly reduced body weight in treated diabetic”
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. (2005, background): “arm indicated that exenatide had a beneficial effect on the -cell (34).”
Incretin-based therapies for type 2 diabetes mellitus (2009, background): “Three pivotal, phase III clinical trials, each of 30 weeks duration, examined the efficacy of twice-daily injections of 5 µg or 10 µg exenatide in individuals who had T2DM that was inadequately controlled with a sulfonylurea and/or metformin”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “…presence did not seem to impact the degree of glycemic control, and 2), increasing titer of antibody also did not seem to be reflected in worsening blood glucose control (Buse et al., 2004; DeFronzo et al., 2005; Heine et al., 2005; Kendall et al., 2005; Nauck et al., 2007a; Zinman et al., 2007).”
SGLT2 inhibition — a novel strategy for diabetes treatment (2010, background): “Newer drugs, such as the incretin mimetics, may produce nausea, vomiting and diarrhoe”